Literature DB >> 26019451

Effect of nuclear factor-κB and angiotensin II receptor type 1 on the pathogenesis of rat non-alcoholic fatty liver disease.

Dao-Yu Tan1, Hai-Yan Shi1, Chang-Ping Li1, Xiao-Ling Zhong1, Ming Kang1.   

Abstract

AIM: To investigate the roles of nuclear factor (NF)-κB and angiotensin II receptor type 1 (AT1R) in the pathogenesis of non-alcoholic fatty liver disease (NAFLD).
METHODS: Forty-two healthy adult male Sprague-Dawley rats were randomly divided into three groups: the control group (normal diet), the model group, and the intervention group (10 wk of a high-fat diet feeding, followed by an intraperitoneal injection of PDTC); 6 rats in each group were sacrificed at 6, 10, and 14 wk. After sacrifice, liver tissue was taken, paraffin sections of liver tissue specimens were prepared, hematoxylin and eosin (HE) staining was performed, and pathological changes in liver tissue (i.e., liver fibrosis) were observed by light microscopy. NF-κB expression in liver tissue was detected by immunohistochemistry, and the expression of AT1R in the liver tissue was detected by reverse transcription-polymerase chain reaction (RT-PCR). The data are expressed as mean ± SD. A two-sample t test was used to compare the control group and the model group at different time points, paired t tests were used to compare the differences between the intervention group and the model group, and analysis of variance was used to compare the model group with the control group. Homogeneity of variance was analyzed with single factor analysis of variance. H variance analysis was used to compare the variance. P < 0.05 was considered statistically significant.
RESULTS: The NAFLD model was successful after 6 wk and 10 wk. Liver fibrosis was found in four rats in the model group, but in only one rat in the intervention group at 14 wk. Liver steatosis, inflammation, and fibrosis were gradually increased throughout the model. In the intervention group, the body mass, rat liver index, serum lipid, and transaminase levels were not increased compared to the model group. In the model group, the degree of liver steatosis was increased at 6, 10, and 14 wk, and was significantly higher than in the control group (P < 0.01). In the model group, different degrees of liver cell necrosis were visible and small leaves, punctated inflammation, focal necrosis, and obvious ballooning degeneration were observed. Partial necrosis and confluent necrosis were observed. In the model group, liver inflammatory activity scores at 6, 10, and 14 wk were higher than in the control group (P < 0.01). Active inflammation in liver tissue in the intervention group was lower than in the model group (P < 0.05). HE staining showed liver fibrosis only at 14 wk in 4/6 rats in the model group and in 1/6 rats in the intervention group. NF-κB positive cells were stained yellow or ensemble yellow, and NF-κB was localized in the cytoplasm and/or nucleus. The model group showed NF-κB activation at 6, 10, and 14 wk in liver cells; at the same time points, there were statistically significant differences in the control group (P < 0.01). Over time, NF-κB expression increased; this was statistically lower (P < 0.05) at 14 weeks in the intervention group compared to the model group, but significantly increased (P < 0.05) compared with the control group; RT-PCR showed that AT1R mRNA expression increased gradually in the model group; at 14 wk, the expression was significantly different compared with expression at 10 weeks as well as at 6 weeks (P < 0.05). In the model group, AT1R mRNA expression was significantly higher than at the same time point in the control group (P < 0.01).
CONCLUSION: With increasing severity of NAFLD, NF-κB activity is enhanced, and the inhibition of NF-κB activity may reduce AT1R mRNA expression in NAFLD.

Entities:  

Keywords:  Angiotensin II receptor type 1; Non-alcoholic fatty liver disease; Nuclear factor-κB; Rats, Liver fibrosis

Mesh:

Substances:

Year:  2015        PMID: 26019451      PMCID: PMC4438021          DOI: 10.3748/wjg.v21.i19.5877

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  31 in total

Review 1.  Viral hepatitis: human genes that limit infection.

Authors:  Frank Grünhage; Jacob Nattermann
Journal:  Best Pract Res Clin Gastroenterol       Date:  2010-10       Impact factor: 3.043

2.  Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  Kaushal Madan; Payal Bhardwaj; Sandeep Thareja; Siddhartha D Gupta; Anoop Saraya
Journal:  J Clin Gastroenterol       Date:  2006 Nov-Dec       Impact factor: 3.062

Review 3.  Mitochondrial involvement in non-alcoholic steatohepatitis.

Authors:  Gaetano Serviddio; Juan Sastre; Francesco Bellanti; José Viña; Gianluigi Vendemiale; Emanuele Altomare
Journal:  Mol Aspects Med       Date:  2007-11-01

Review 4.  Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.

Authors:  Ahmed M Elsharkawy; Derek A Mann
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

5.  RanBPM interacts with TβRI, TRAF6 and curbs TGF induced nuclear accumulation of TβRI.

Authors:  Junwen Zhang; Wen Ma; Shuo Tian; Zhenzhen Fan; Xiaoli Ma; Xia Yang; Qiaojiajie Zhao; Kuan Tan; Hong Chen; Deng Chen; Bing-Ren Huang
Journal:  Cell Signal       Date:  2013-10-06       Impact factor: 4.315

6.  Prevalence and associated metabolic factors of fatty liver disease in the elderly.

Authors:  Zhongli Wang; Ming Xu; Jianhong Peng; Li Jiang; Zhengguo Hu; Hua Wang; Shiqing Zhou; Rui Zhou; Michael Hultström; En Yin Lai
Journal:  Exp Gerontol       Date:  2013-05-27       Impact factor: 4.032

Review 7.  Structural determinants of DISC function: new insights into death receptor-mediated apoptosis signalling.

Authors:  Tamas Sessler; Sandra Healy; Afshin Samali; Eva Szegezdi
Journal:  Pharmacol Ther       Date:  2013-07-08       Impact factor: 12.310

8.  Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease.

Authors:  Masato Yoneda; Kikuko Hotta; Yuichi Nozaki; Hiroki Endo; Takashi Uchiyama; Hironori Mawatari; Hiroshi Iida; Shingo Kato; Koji Fujita; Hirokazu Takahashi; Hiroyuki Kirikoshi; Noritoshi Kobayashi; Masahiko Inamori; Yasunobu Abe; Kensuke Kubota; Satoru Saito; Shiro Maeyama; Koichiro Wada; Atsushi Nakajima
Journal:  Liver Int       Date:  2009-03-03       Impact factor: 5.828

9.  Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease.

Authors:  Lake Li; Jie Hai; Zhiqiang Li; Yongli Zhang; Hua Peng; Kun Li; Xiaogang Weng
Journal:  Food Chem Toxicol       Date:  2013-08-24       Impact factor: 6.023

10.  Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation.

Authors:  Yizhe Cui; Qiuju Wang; Xiaochong Li; Xiuying Zhang
Journal:  Redox Biol       Date:  2013-08-24       Impact factor: 11.799

View more
  2 in total

1.  Dietary Flaxseed Oil Prevents Western-Type Diet-Induced Nonalcoholic Fatty Liver Disease in Apolipoprotein-E Knockout Mice.

Authors:  Hao Han; Fubin Qiu; Haifeng Zhao; Haiying Tang; Xiuhua Li; Dongxing Shi
Journal:  Oxid Med Cell Longev       Date:  2017-09-07       Impact factor: 6.543

2.  Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.

Authors:  Jia-Min Yang; Yan Sun; Min Wang; Xin-Lei Zhang; Shu-Jing Zhang; Yu-Shan Gao; Lin Chen; Meng-Yao Wu; Lu Zhou; Yu-Mei Zhou; Yue Wang; Feng-Jie Zheng; Yu-Hang Li
Journal:  World J Gastroenterol       Date:  2019-09-14       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.